Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $2.9 million.

  • Aclaris Therapeutics' Share-based Compensation fell 479.36% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 3299.5%. This contributed to the annual value of $10.9 million for FY2024, which is 4715.22% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Share-based Compensation stood at $2.9 million for Q3 2025, which was down 479.36% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Share-based Compensation ranged from a high of $6.8 million in Q1 2023 and a low of $1.3 million during Q4 2023
  • In the last 5 years, Aclaris Therapeutics' Share-based Compensation had a median value of $3.5 million in 2025 and averaged $3.7 million.
  • Data for Aclaris Therapeutics' Share-based Compensation shows a peak YoY increase of 19011.08% (in 2023) and a maximum YoY decrease of 7369.62% (in 2023) over the last 5 years.
  • Aclaris Therapeutics' Share-based Compensation (Quarter) stood at $3.9 million in 2021, then grew by 24.98% to $4.8 million in 2022, then tumbled by 73.7% to $1.3 million in 2023, then skyrocketed by 125.91% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
  • Its Share-based Compensation was $2.9 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.5 million in Q1 2025.